Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Rac1/Wave2/Arp3 Pathway Mediates Rat Blood-Brain Barrier Dysfunction under Simulated Microgravity Based on Proteomics Strategy.

Tytuł:
Rac1/Wave2/Arp3 Pathway Mediates Rat Blood-Brain Barrier Dysfunction under Simulated Microgravity Based on Proteomics Strategy.
Autorzy:
Yan R; School of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China.
Liu H; School of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China.
Lv F; School of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China.
Deng Y; School of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China.
Li Y; School of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 May 13; Vol. 22 (10). Date of Electronic Publication: 2021 May 13.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Gene Expression Regulation*
Actin-Related Protein 3/*metabolism
Blood-Brain Barrier/*pathology
Proteome/*metabolism
Weightlessness Simulation/*adverse effects
Wiskott-Aldrich Syndrome Protein Family/*metabolism
rac1 GTP-Binding Protein/*metabolism
Actin Cytoskeleton ; Animals ; Blood-Brain Barrier/metabolism ; Male ; Proteome/analysis ; Rats ; Rats, Sprague-Dawley ; Signal Transduction ; Tight Junctions
References:
J Proteome Res. 2016 Jan 4;15(1):29-37. (PMID: 26523826)
J Cell Sci. 2003 Nov 15;116(Pt 22):4605-13. (PMID: 14576354)
Biochem Biophys Res Commun. 2020 Jun 11;526(4):1077-1084. (PMID: 32312522)
Prog Neurobiol. 2018 Feb;161:79-96. (PMID: 29217457)
FASEB J. 2020 Nov;34(11):15516-15530. (PMID: 32981077)
PLoS One. 2013 May 10;8(5):e63553. (PMID: 23675488)
Int J Mol Sci. 2019 Jun 28;20(13):. (PMID: 31261642)
Fluids Barriers CNS. 2012 Jun 29;9(1):11. (PMID: 22569151)
Curr Top Membr. 2018;82:141-195. (PMID: 30360779)
Int J Biochem Cell Biol. 2010 Oct;42(10):1614-7. (PMID: 20601080)
Cell Biol Int. 2014 Mar;38(3):283-6. (PMID: 24497348)
Int J Mol Sci. 2018 Nov 23;19(12):. (PMID: 30477143)
Brain Res. 2019 Sep 1;1718:231-241. (PMID: 31034813)
J Cell Sci. 1999 Jun;112 ( Pt 11):1655-69. (PMID: 10318759)
Int J Mol Sci. 2020 Jan 28;21(3):. (PMID: 32013031)
Mol Biol Cell. 2014 Jan;25(2):245-56. (PMID: 24227887)
BMB Rep. 2014 Dec;47(12):655-9. (PMID: 25388208)
J Cutan Pathol. 2002 Aug;29(7):430-8. (PMID: 12139639)
Int J Mol Sci. 2019 Nov 03;20(21):. (PMID: 31684130)
Nat Med. 2019 Feb;25(2):270-276. (PMID: 30643288)
Front Cell Neurosci. 2019 Aug 06;13:360. (PMID: 31447648)
Life (Basel). 2014 Jul 03;4(3):281-94. (PMID: 25370373)
Oncotarget. 2017 Apr 7;8(35):58430-58442. (PMID: 28938568)
Curr Biol. 2010 Feb 23;20(4):339-45. (PMID: 20137952)
Sci Rep. 2019 Jul 18;9(1):10460. (PMID: 31320676)
Cell Biol Int. 2009 Aug;33(8):893-8. (PMID: 19426823)
Bone. 2016 Jun;87:44-56. (PMID: 27032715)
J Biochem Mol Toxicol. 2019 May;33(5):e22294. (PMID: 30664321)
Cell Mol Gastroenterol Hepatol. 2016 Oct 22;3(1):41-50. (PMID: 28174756)
Cell Biol Int. 2016 Mar;40(3):241-56. (PMID: 26909547)
Mol Med Rep. 2016 May;13(5):4414-20. (PMID: 27052944)
Sci Adv. 2015 Sep 4;1(8):e1500472. (PMID: 26491725)
FASEB J. 2014 Jun;28(6):2551-65. (PMID: 24604078)
J Cell Biochem. 2007 Aug 15;101(6):1439-55. (PMID: 17340622)
J Clin Pharmacol. 2004 Aug;44(8):837-53. (PMID: 15286087)
Ecotoxicol Environ Saf. 2010 Mar;73(3):456-63. (PMID: 19913298)
Immunol Cell Biol. 2017 Oct;95(9):843-853. (PMID: 28682305)
J Neuroinflammation. 2019 Jan 24;16(1):15. (PMID: 30678702)
Nutrition. 2002 Oct;18(10):889-98. (PMID: 12361784)
Exp Transl Stroke Med. 2015 Jan 28;7(1):3. (PMID: 25642315)
Cell Adh Migr. 2014;8(2):125-35. (PMID: 24621569)
Nat Cell Biol. 2015 Dec;17(12):1597-606. (PMID: 26523364)
J Biol Chem. 2016 Feb 5;291(6):2548-55. (PMID: 26728462)
J Exp Clin Cancer Res. 2015 Jan 31;34:8. (PMID: 25636908)
Radiat Res. 2017 Oct;188(4):392-399. (PMID: 28763287)
J Neural Transm (Vienna). 2018 Jun;125(6):899-912. (PMID: 29332257)
Nat Neurosci. 2017 Dec;20(12):1752-1760. (PMID: 29184215)
Physiol Res. 2020 Nov 16;69(5):897-906. (PMID: 32901501)
Front Physiol. 2017 Aug 02;8:547. (PMID: 28824446)
Free Radic Res. 2009 Apr;43(4):348-64. (PMID: 19241241)
PLoS Biol. 2019 Oct 10;17(10):e3000457. (PMID: 31600188)
Oncotarget. 2017 Dec 21;9(4):4897-4914. (PMID: 29435150)
J Neuroimmune Pharmacol. 2006 Sep;1(3):223-36. (PMID: 18040800)
Microvasc Res. 2012 Jan;83(1):3-11. (PMID: 21864544)
J Appl Physiol (1985). 2002 Apr;92(4):1367-77. (PMID: 11895999)
J Cell Biol. 2002 Dec 9;159(5):881-91. (PMID: 12473693)
Int J Mol Sci. 2018 Dec 20;20(1):. (PMID: 30577490)
Brain Res Bull. 2020 Dec;165:253-262. (PMID: 33141074)
Biochim Biophys Acta. 2008 Mar;1778(3):660-9. (PMID: 17854762)
Front Immunol. 2017 Aug 09;8:902. (PMID: 28848542)
Mol Neurobiol. 2015 Oct;52(2):867-81. (PMID: 26133300)
Front Physiol. 2019 Dec 03;10:1455. (PMID: 31849705)
J Ethnopharmacol. 2020 Jan 10;246:112243. (PMID: 31541722)
Sci Rep. 2018 Feb 28;8(1):3769. (PMID: 29491429)
Bioorg Med Chem Lett. 2014 Feb 15;24(4):1176-9. (PMID: 24440300)
Mol Biol Cell. 2007 Nov;18(11):4591-602. (PMID: 17855511)
Eur Rev Med Pharmacol Sci. 2017 Nov;21(22):5275-5282. (PMID: 29228445)
Aviat Space Environ Med. 2000 Jun;71(6):640-6. (PMID: 10870824)
Curr Opin Cell Biol. 2005 Apr;17(2):123-8. (PMID: 15780587)
Aviat Space Environ Med. 2007 Oct;78(10):932-6. (PMID: 17955940)
J Cell Biol. 2011 Jan 24;192(2):307-19. (PMID: 21242289)
J Cereb Blood Flow Metab. 2010 Dec;30(12):1939-50. (PMID: 20354546)
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):274-279. (PMID: 30449598)
FASEB J. 2013 May;27(5):2045-54. (PMID: 23363573)
Cell Motil Cytoskeleton. 2004 Jul;58(3):143-59. (PMID: 15146534)
J Proteomics. 2017 May 8;160:64-73. (PMID: 28341594)
Grant Information:
81973572 National Natural Science Foundation of China; 81573693 National Natural Science Foundation of China
Contributed Indexing:
Keywords: HBMECs; Rac1/Wave2/Arp3; blood-brain barrier; proteomics; simulated microgravity
Substance Nomenclature:
0 (Actin-Related Protein 3)
0 (Proteome)
0 (Wiskott-Aldrich Syndrome Protein Family)
EC 3.6.1.- (Rac1 protein, rat)
EC 3.6.5.2 (rac1 GTP-Binding Protein)
Entry Date(s):
Date Created: 20210602 Date Completed: 20210610 Latest Revision: 20210610
Update Code:
20240104
PubMed Central ID:
PMC8153163
DOI:
10.3390/ijms22105165
PMID:
34068233
Czasopismo naukowe
The blood-brain barrier (BBB) is critical to maintaining central nervous system (CNS) homeostasis. However, the effects of microgravity (MG) on the BBB remain unclear. This study aimed to investigate the influence of simulated MG (SMG) on the BBB and explore its potential mechanism using a proteomic approach. Rats were tail-suspended to simulate MG for 21 days. SMG could disrupt the BBB, including increased oxidative stress levels, proinflammatory cytokine levels, and permeability, damaged BBB ultrastructure, and downregulated tight junctions (TJs) and adherens junctions (AJs) protein expression in the rat brain. A total of 554 differentially expressed proteins (DEPs) induced by SMG were determined based on the label-free quantitative proteomic strategy. The bioinformatics analysis suggested that DEPs were mainly enriched in regulating the cell-cell junction and cell-extracellular matrix biological pathways. The inhibited Ras-related C3 botulinum toxin substrate 1 (Rac1)/Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 (Wave2)/actin-related protein 3 (Arp3) pathway and the decreased ratio of filamentous actin (F-actin) to globular actin contributed to BBB dysfunction induced by SMG. In the human brain microvascular endothelial cell (HBMECs), SMG increased the oxidative stress levels and proinflammatory cytokine levels, promoted apoptosis, and arrested the cell cycle phase. Expression of TJs and AJs proteins were downregulated and the distribution of F-actin was altered in SMG-treated HBMECs. The key role of the Rac1/Wave2/Arp3 pathway in BBB dysfunction was confirmed in HBMECs with a specific Rac1 agonist. This study demonstrated that SMG induced BBB dysfunction and revealed that Rac1/Wave2/Arp3 could be a potential signaling pathway responsible for BBB disruption under SMG. These results might shed a novel light on maintaining astronaut CNS homeostasis during space travel.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies